Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3047% below fair value
$1.24−0.08 (-6.44%)
Close on Nov 17, 2026Market cap $5.68MP/E –Yield –
Biomerica profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Biomerica's profit margin for the twelve months ending Aug 31, 2026 was -115.5%. For fiscal 2026 it was -84.8%, against -93.6% the year before. The highest annual figure on record is 9.0% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | May 31, 2026 | -84.8% | +8.9 |
| FY2025 | May 31, 2025 | -93.6% | +16.8 |
| FY2024 | May 31, 2024 | -110.4% | +23.3 |
| FY2023 | May 31, 2023 | -133.7% | −109.7 |
| FY2022 | May 31, 2022 | -24.0% | +79.4 |
| FY2021 | May 31, 2021 | -103.4% | −63.4 |
| FY2020 | May 31, 2020 | -40.0% | +6.0 |
| FY2019 | May 31, 2019 | -46.0% | −19.7 |
| FY2018 | May 31, 2018 | -26.3% | −10.7 |
| FY2017 | May 31, 2017 | -15.7% | +13.5 |
| FY2016 | May 31, 2016 | -29.2% | −22.5 |
| FY2015 | May 31, 2015 | -6.7% | −2.5 |
| FY2014 | May 31, 2014 | -4.2% | −12.5 |
| FY2013 | May 31, 2013 | 8.3% | −0.7 |
| FY2012 | May 31, 2012 | 9.0% | +5.8 |
| FY2011 | May 31, 2011 | 3.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -97.4% | −97.5 |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -130.9% | +75.3 |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -132.9% | −29.0 |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -109.1% | −51.0 |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | 0.1% | +73.0 |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -206.1% | −78.8 |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -103.9% | +84.7 |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -58.1% | +38.1 |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -72.8% | −6.7 |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -127.3% | +34.4 |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -188.6% | −40.1 |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -96.2% | +13.5 |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -66.1% | +60.5 |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -161.7% | −128.6 |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -148.5% | −147.2 |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -109.7% | −85.5 |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -126.6% | −4.3 |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -33.2% | +129.2 |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -1.4% | +57.2 |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -24.2% | +101.0 |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -122.3% | +43.2 |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -162.3% | −132.1 |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -58.5% | +14.6 |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -125.2% | −94.8 |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -165.4% | −123.1 |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -30.3% | +37.1 |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -73.2% | −19.3 |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -30.4% | +1.4 |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -42.4% | −6.9 |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -67.4% | −8.3 |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -53.8% | −30.4 |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -31.8% | −15.2 |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -35.5% | −21.2 |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -59.1% | −35.2 |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -23.4% | −3.2 |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -16.6% | −2.5 |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -14.3% | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -23.9% | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -20.3% | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -14.2% | – |
See a number that looks wrong?